Arno Therapeutics, Inc.
ARNI
Rank in Stocks
#34676
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Share Price
$0.0001
Last synced: 2026-11-10
Market Cap
$4.47K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Arno Therapeutics, Inc. (ARNI)
Category
Healthcare
EPS for Arno Therapeutics, Inc. (ARNI)
EPS as of September 2016 TTM: $-0.43
According to Arno Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.43. At the end of 2015 the company had an EPS of $-0.57, a decrease compared to its 2014 EPS of $0.38.
EPS history for Arno Therapeutics, Inc. from 2003 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.43 | -24.56% |
| 2015 | $-0.57 | -250.00% |
| 2014 | $0.38 | -104.90% |
| 2013 | $-7.75 | 69.58% |
| 2012 | $-4.57 | 140.53% |
| 2011 | $-1.90 | 20.25% |
| 2010 | $-1.58 | -41.91% |
| 2009 | $-2.72 | -57.83% |
| 2008 | $-6.45 | -21,671.91% |
| 2007 | $0.03 | -144.89% |
| 2006 | $-0.07 | -3.62% |
| 2005 | $-0.07 | 40.16% |
| 2004 | $-0.05 | -69.19% |
| 2003 | $-0.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,741.86% |
US
|
|
| $-7.07 | 1,544.19% |
US
|
|
| $-5.29 | 1,130.23% |
AU
|
|
| $12.88 | -3,095.37% |
BE
|
|
| $21.56 | -5,113.95% |
NL
|
Questions about Arno Therapeutics, Inc.'s earnings per share (EPS)
What is Arno Therapeutics, Inc.'s earnings per share (EPS)?
Arno Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.43, as of Sep 2016.
What was Arno Therapeutics, Inc.'s earnings per share (EPS) in 2015?
In 2015, Arno Therapeutics, Inc.'s earnings per share (EPS) was $-0.57, compared with $0.38 in 2014.
How has Arno Therapeutics, Inc.'s earnings per share (EPS) changed since 2010?
From 2010 to 2015, Arno Therapeutics, Inc.'s earnings per share (EPS) was highest in 2014 ($0.38) and lowest in 2013 ($-7.75).
How does Arno Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Arno Therapeutics, Inc.'s earnings per share (EPS) ($-0.43) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.